Sarepta Therapeutics Looms as Analysts Initiate Coverage

Author: Thomas Cooper Updated: 07-24-2025 08:59 AM

Analyst Changes for Leading Biotech Stocks

Recent shifts in analyst perspectives promise to impact the investment landscape. The focus is on various companies, including Sarepta Therapeutics Inc. This company, known for its innovative therapies for rare diseases, has sparked interest with analysts sharing their insights and ratings.

Canaccord Genuity's View on Sagimet Biosciences Inc

First on the list is Sagimet Biosciences Inc. Canaccord Genuity analyst Edward Nash has initiated coverage on this biotech firm with a positive outlook, giving it a Buy rating and setting a price target of $28. The stock has shown significant potential, closing at $9.59 recently.

Citigroup's Perspective on Sarepta Therapeutics

In a stark contrast, Citigroup analyst Yigal Nochomovitz has initiated coverage on Sarepta Therapeutics, Inc. with a Sell rating, suggesting caution. The target price has been set at $7, with the stock recently closing at $13.32. Analysts often provide insights into a company's future potential and risks, which is crucial for investors to consider.

Cantor Fitzgerald on Eupraxia Pharmaceuticals Inc

Cantor Fitzgerald's analyst Kristen Kluska has begun coverage on Eupraxia Pharmaceuticals Inc., giving it an Overweight rating. She has pegged the price target at $11, with the stock previously closing at $5.06. This reflects optimism about Eupraxia's pipeline and product offerings.

B of A Securities Initiation on Elbit Systems Ltd

Meanwhile, B of A Securities analyst Ronald Epstein has issued a Buy rating for Elbit Systems Ltd., highlighting a price target of $500. With shares closing at $445.97 recently, this recommendation underscores the belief in the company's continued growth in the defense and technology sector.

Mizuho's Take on Braze, Inc.

Mizuho analyst Siti Panigrahi recently completed her coverage initiation for Braze, Inc., assigning an Outperform rating and a price target of $40. Braze shares are currently trading at $28.44, indicating a strong belief in the company’s ability to thrive.

Market Trends and Analyst Sentiments

As evident from these changes, analyst sentiments play a significant role in shaping the stock market. The contrasting ratings highlight the varied outlooks on different stocks, stressing the need for diligent research when making investment choices.

Investment Considerations for SRPT Stock

Considering investing in SRPT stock? Analysts suggest a cautious approach given the Sell rating from Citigroup. However, staying informed about market dynamics and analyst insights can provide valuable perspectives for investors.

Frequently Asked Questions

What is the latest coverage on Sarepta Therapeutics?

Analysts have provided a Sell rating for Sarepta Therapeutics from Citigroup, indicating potential concerns regarding its stock performance.

Which analysts initiated coverage on Sagimet Biosciences Inc?

Canaccord Genuity's Edward Nash initiated coverage with a Buy rating and a price target of $28 on Sagimet Biosciences Inc.

What rating did Cantor Fitzgerald give to Eupraxia Pharmaceuticals?

Cantor Fitzgerald initiated an Overweight rating for Eupraxia Pharmaceuticals with a $11 price target.

What is the price target for Elbit Systems Ltd according to B of A Securities?

B of A Securities set a Buy rating for Elbit Systems Ltd with a price target of $500.

How can I invest in Braze, Inc.?

Mizuho's coverage initiated an Outperform rating for Braze, Inc., with a price target of $40, suggesting a positive outlook for potential investors.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.